TAIYO HOLDINGS CO., LTD.

InstagramYou Tube
CLOSE
HOME > Investor Relations > Financial Highlights

Financial Highlights

At a Glance

  • Sales by Reportable Segments

    Sales by Reportable Segments

  • Operating Profit and Operating Profit Ratio on Sales

    Operating Profit and Operating Profit Ratio on Sales<

  • Net Income and Return on Equity

    Net Income and Return on Equity

(Unit: millions of yen)

FY
2016		 FY
2017		 FY
2018		 FY
2019		 FY
2020
Sales by Reportable Segments 49,843 47,866 52,241 59,389 70,627
Electonics Materials 48,302 46,450 49,854 48,086 48,884
Medical and Pharmaceuticals － － 819 7,661 18,215
Other 1,540 1,415 1,567 3,642 3,527
Operating Profit 10,964 9,221 11,337 8,099 9,136
Net Income 7,796 6,398 4,856 4,443 3,806
Operating Profit Ratio on Sales (%) 22.0 19.3 21.7 13.6 12.9
Return on Equity (%) 19.0 11.2 6.8 6.2 5.4

Financial Indicators

  • Total Assets and Return on Assets

    Total Assets and Return on Assets

  • Shareholders' Equity and Shareholders' Equity Ratio

    Shareholders' Equity and Shareholders' Equity Ratio

  • Capital Expenditure

    Capital Expenditure

  • Depreciation and
    Amortization Expenditure

    Depreciation and Amortization Expenditure

  • R&D Expenditure

    R&D Expenditure

  • Number of Employees

    Number of Employees

(Unit: millions of yen)

FY
2016		 FY
2017		 FY
2018		 FY
2019		 FY
2020
Total Assets 65,464 92,386 111,490 105,666 142,192
Shareholders' Equity 43,115 71,063 72,659 70,183 69,222
Capital Expenditure 4,055 1,722 (※1) 1,565 6,924 (※3) 6,916
Depreciation and
Amortization Expenditure		 1,891 2,485 (※2) 1,941 (※2) 2,557 (※2) 3,566
R&D Expenditure 2,441 3,235 3,089 3,116 3,312
Return on Assets (%) 11.9 6.9 4.4 4.2 2.6
Shareholders' Equity Ratio (%) 65.9 76.9 65.2 66.4 48.7
Number of Employees 1,202 1,249 1,268 1,614 1,988

※1 Capital expenditure does not include sales rights of 13 long-term listed products.

※2 Depreciation does not include amortization of sales rights of long0term listed products.

※3 Capital expenditure does not include goodwill of TAIYO Pharma-Tech.